This document summarizes a study that evaluated the prognostic impact of the human Chitinase 3-like 1 (CHI3L1) biomarker in adult patients with acute myeloid leukemia (AML). The study found that high initial levels of CHI3L1 correlated with worse overall survival and disease-free survival in AML patients. While high CHI3L1 levels did not predict response to induction chemotherapy, normalization of initially high levels after treatment was associated with better response. The study concludes that CHI3L1 shows potential as a prognostic biomarker for outcomes in AML patients.